Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Structural Genomics Consortium
Structural Genomics Consortium
Activities:
Research & Development
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Research & Development
Myeloma UK and the Structural Genomics Consortium link up to discover new drug targets for myeloma
The open-access collaboration will make all reagents and knowledge available to pharma, biotech and academic research groups
Research & Development
Takeda invests CA$7.5m in Structural Genomics Consortium to fund collective drug research
Renewing a partnership that started in 2012
Research & Development
Drug discovery: a job too complex for academia or industry alone?
<b>5 - 6 January 2012</b><br> <i>Two-day conference</i><br> Oxford, UK
Research & Development
SGC provides funding of US$49m to support drug discovery
Eli Lilly and Pfizer join the Structural Genomics Consortium
Subscribe now